Results 111 to 120 of about 653,222 (236)
Current treatment differences before 2003 and in 2009 in seasonal allergic rhinitis
, 2010 Objective: To evaluate the differences of seasonal allergic rhinitis (SR) treatment options which patients were receiving at admission to our clinic and provided by us later according to Allergic Rhinitis and its Impact on Asthma (ARIA)
KALYONCU, ALİ FUAT +3 more
core
Clinical &Experimental Allergy, EarlyView.A Phase 1, randomised, placebo‐controlled, dose‐escalation trial was performed with 30 birch pollen allergic subjects treated with DM‐101PX, that contains a recombinant hypoallergenic variant of Bet v 1 formulated with poloxamer 338 thermosensitive hydrogel.
Anna Nilson +14 more
wiley +1 more source
Traditional &Kampo Medicine, Volume 13, Issue 3, December 2026.ABSTRACT Aim To evaluate the efficacy and safety of adjunctive shoseiryuto, a traditional Japanese Kampo medicine, in patients with refractory eosinophilic chronic rhinosinusitis (ECRS), with particular attention to mucus‐related symptoms. Methods This retrospective pilot case series was conducted at Osaka Medical and Pharmaceutical University Hospital
Yusuke Kikuoka
wiley +1 more source
, 2014 Pooled Analysis for NSS of leukotriene antagonist versus selective H1 antihistamine for Seasonal allergic rhinitis.
Jun Wang (5906) +2 more
core +1 more source
Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.ABSTRACT Background The mannan‐conjugated birch pollen polymerised allergoid EP‐088_T502 has previously been shown to reduce allergic symptoms and anti‐allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP‐088_T502 administered as ...
Esther Raskopf +14 more
wiley +1 more source
New aspects of allergic rhinitis treatment
, 2019 Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in different countries. Allergic rhinitis affects negative on the quality of patient’s life and is often associated with asthma.
Olga M. Kolesnikova +1 more
core +1 more source
Stapokibart (CM310): A review in seasonal allergic rhinitis
American Journal of OtolaryngologyStapokibart (CM310), a humanized anti-IL-4Rα monoclonal antibody, blocks IL-4/IL-13 signaling for type 2 inflammatory diseases like seasonal allergic rhinitis (SAR), where standard of care often fails.Assess stapokibart's efficacy on the primary endpoint (reflective Total Nasal Symptom Score, rTNSS) and safety as add-on therapy in SoC-inadequate ...
Ping, Xue, Jing, Yan, Jianwei, Li
openaire +2 more sources
A Survey on Seasonal Symptoms in Subjects with and Without Allergic Rhinitis Diagnosis
In Switzerland, only scarce data are available on the prevalence and treatment of allergic rhinitis. Although the presence of AR symptoms in temporal relation to the respective aeroallergen is indicative, still a substantial number of affected ...
Victor Colin +6 more
core +1 more source
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background and Aims Acoustic nasal therapy has emerged as a potential non‐pharmacological adjunct for allergic rhinitis (AR) and chronic rhinosinusitis (CRS), but longitudinal evidence on its effects on nasal airflow and patient‐reported outcomes remains limited.
Jude Oluwapelumi Alao +5 more
wiley +1 more source
Trends in Aeroallergen IgE Sensitization in Jordan: A Decade‐Long Observational Study
Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.ABSTRACT Background Inhalant allergies from airborne allergens, such as pollen, dust mites, and animal dander, substantially contribute to allergic respiratory diseases globally. Sensitization to aeroallergens is influenced by environmental, urban, and climatic factors and demographic characteristics, including age and sex. However, long‐term data from
Jumana Abu‐Kwaik +6 more
wiley +1 more source